COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program

In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.

Businessman on blurred background holding and touching floating stethoscope 3D rendering - Image

The COVID-19 pandemic has provided US regulators with a unique opportunity to test whether they can successfully use remote monitoring to evaluate the performance of firms making software as a medical device (SaMD). So far, it seems it is a viable option, a new report says.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation